AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14514589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled regular insulin (80, 160, or 240 units) via Aerodose insulin inhaler
Number of subjects: 24
Study 14514589 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously injected regular insulin (8, 16, or 24 units)
Number of subjects: 24
Study 14514589 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of total insulin absorption (insulin AUC) versus total metabolic effect (GIR-AUC)
Number of subjects: 24
Study 10718776 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg single oral dose)
Number of subjects: 21
Study 10718776 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol clearance (predictor of renal function)
Number of subjects: 21
Study 9388983 — intervention group
Group type: EXPERIMENTAL
Intervention: Heng Nai Jin, a high energy liquid diet
Number of subjects: 2
Study 9388983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 1417176 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemosurgery (n = 73)
Number of subjects: 6589
Study 1417176 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemosurgery (n = 159)
Number of subjects: 6589
Study 1417176 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n = 64)
Number of subjects: 6589
Study 1417176 — intervention group
Group type: COMPARATOR
Intervention: Surgery and chemotherapy (n = 77)
Number of subjects: 6589
Study 1417176 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n = 94)
Number of subjects: 6589
Study 6496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (poison-warning stickers after education)
Number of subjects: 20
Study 6496418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 20
Study 31941594 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-docking robotic-assisted nephroureterectomy (RRNU)
Number of subjects: 29
Study 31941594 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical nephroureterectomy (LRNU)
Number of subjects: 29
Study 31484331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled potatoes (high RS)
Number of subjects: 30
Study 31484331 — intervention group
Group type: COMPARATOR
Intervention: Boiled potatoes (low RS)
Number of subjects: 30
Study 26365441 — intervention group
Group type: EXPERIMENTAL
Intervention: SentiMag®
Number of subjects: 193
Study 26365441 — intervention group
Group type: COMPARATOR
Intervention: 99m Tc
Number of subjects: 193
Study 25586295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate (75mg)
Number of subjects: 0
Study 25586295 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate (75mg)
Number of subjects: 0
Study 24676274 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish animated video about diabetes
Number of subjects: 240
Study 24676274 — intervention group
Group type: COMPARATOR
Intervention: Easy to read diabetes information from the National Institute of Diabetes and Digestive and Kidney Diseases (control)
Number of subjects: 240
Study 22199063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment, twice daily for 6 months
Number of subjects: 60
Study 22199063 — intervention group
Group type: COMPARATOR
Intervention: 0.05% fluticasone propionate cream, once daily for 6 months
Number of subjects: 60
Study 21589776 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (head, neck, face, shoulder, hand, leg, and back massage every night for one month)
Number of subjects: 60
Study 21589776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention except standard treatment)
Number of subjects: 60
Study 18416219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular starch in combination with Ringer Lactate solution (LMSRL)
Number of subjects: 180
Study 18416219 — intervention group
Group type: COMPARATOR
Intervention: Gelatin plasma expanding (GPE)
Number of subjects: 180
Study 15812403 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG placement with overtube (Group I)
Number of subjects: 73
Study 15812403 — intervention group
Group type: COMPARATOR
Intervention: PEG placement without overtube (Group II)
Number of subjects: 73
Study 12733605 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance tests
Number of subjects: 0
Study 12733605 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no resistance tests)
Number of subjects: 0
Study 9477047 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group (n = 14)
Number of subjects: 44
Study 9477047 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 44
Study 9477047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC group (n = 9)
Number of subjects: 44
Study 9477047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC group (n = 6)
Number of subjects: 44
Study 7880161 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback provided to staff concerning the lifestyle of participants
Number of subjects: 33
Study 2224167 — intervention group
Group type: EXPERIMENTAL
Intervention: First line chemotherapy (monthly FEC)
Number of subjects: 0
Study 2224167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonotherapy
Number of subjects: 0
Study 2224167 — intervention group
Group type: EXPERIMENTAL
Intervention: Loco-regional metastases
Number of subjects: 0
Study 2224167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant adriamycin containing regimen
Number of subjects: 0
Study 487347 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram implant
Number of subjects: 100
Study 487347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 487347 — intervention group
Group type: COMPARATOR
Intervention: No-implant control
Number of subjects: 100
Study 30157531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal intervention for 2 days during a 5-day hospital stay
Number of subjects: 15
Study 30157531 — intervention group
Group type: COMPARATOR
Intervention: Diabetes adapted diet only (control)
Number of subjects: 15
Study 30157531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal intervention
Number of subjects: 15
Study 27869305 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, or 12 mg
Number of subjects: 1643
Study 27869305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1643
Study 27869305 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (SGS group)
Number of subjects: 1643
Study 27869305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SGS group)
Number of subjects: 1643
Study 27869305 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg (PGTCS group)
Number of subjects: 1643
Study 27869305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PGTCS group)
Number of subjects: 1643
Study 26536865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-sampling for HPV testing
Number of subjects: 1521
Study 26536865 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling participation
Number of subjects: 1521
Study 26536865 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in self-sampling
Number of subjects: 1521
Study 23664436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 1435
Study 23664436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 1435
Study 23664436 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1435
Study 21059666 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (3 times a week for 4 weeks)
Number of subjects: 24
Study 21059666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 21059666 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program
Number of subjects: 24
Study 19526809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 50
Study 19526809 — intervention group
Group type: COMPARATOR
Intervention: Control group (anesthetized with sevoflurane and intermittent i.v. sulfenany and vecurnium bromide)
Number of subjects: 50
Study 19526809 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TAES and Control
Number of subjects: 50
Study 17945070 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae vaccination as an adjunct to anti-tuberculosis treatment
Number of subjects: 751
Study 17945070 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-tuberculosis treatment without Mycobacterium vaccae vaccination)
Number of subjects: 751
Study 17945070 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mortality between sites
Number of subjects: 751
Study 16297299 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group NS), 15 infants
Number of subjects: 36
Study 16297299 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyelectrolyte solution (group PS), 21 infants
Number of subjects: 36
Study 11916817 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 3 ILM
Number of subjects: 100
Study 11916817 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 4 ILM
Number of subjects: 100
Study 11916817 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 ILM
Number of subjects: 100
Study 11916817 — intervention group
Group type: EXPERIMENTAL
Intervention: All ILM sizes
Number of subjects: 100
Study 9895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Urolase fiber
Number of subjects: 93
Study 9895265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraline fiber
Number of subjects: 93
Study 7608359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 1044
Study 7608359 — intervention group
Group type: COMPARATOR
Intervention: No gum use
Number of subjects: 1044
Study 7608359 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help materials
Number of subjects: 1044
Study 7608359 — intervention group
Group type: COMPARATOR
Intervention: No use of materials
Number of subjects: 1044
Study 2375819 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy skills training course
Number of subjects: 0
Study 709021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypaque 85
Number of subjects: 40
Study 709021 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 76
Number of subjects: 40
Study 709021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 40
Study 30617130 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD (doxorubicin, vinblastine, dacarbazine plus brentuximab vedotin)
Number of subjects: 497
Study 30617130 — intervention group
Group type: COMPARATOR
Intervention: ABVD (doxorubicin, vinblastine, dacarbazine, and bleomycin)
Number of subjects: 497
Study 28782136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 month multi-faceted intervention
Number of subjects: 0
Study 28782136 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-adjacent county sports clubs)
Number of subjects: 0
Study 28782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 26814307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1,200 mg
Number of subjects: 376
Study 26814307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 2,400 mg
Number of subjects: 376
Study 26814307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 3,600 mg
Number of subjects: 376
Study 26814307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 24665887 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus device (FRD)
Number of subjects: 36
Study 24665887 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class II malocclusion)
Number of subjects: 36
Study 22993294 — intervention group
Group type: EXPERIMENTAL
Intervention: STX209 (arbaclofen)
Number of subjects: 63
Study 22993294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20201934 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 245
Study 17698196 — intervention group
Group type: COMPARATOR
Intervention: Focal photocoagulation at baseline (n = 19)
Number of subjects: 121
Study 17698196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22)
Number of subjects: 121
Study 17698196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24)
Number of subjects: 121
Study 17698196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22)
Number of subjects: 121
Study 17698196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks (n = 22)
Number of subjects: 121
Study 16417695 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from a nurse
Number of subjects: 1140
Study 16417695 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from a well-known celebrity (Claire Rayner)
Number of subjects: 1140
Study 16417695 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from the local NHS Cervical Screening Commissioner
Number of subjects: 1140
Study 16417695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no action)
Number of subjects: 1140
Study 12421428 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% insulin lispro and 50% neutral protamine lispro (Mix50)
Number of subjects: 109
Study 10523401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 1 (on awakening)
Number of subjects: 240
Study 10523401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 2 (8 hours after awakening)
Number of subjects: 240
Study 10523401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 3 (before bedtime)
Number of subjects: 240
Study 10523401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 10523401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (any time) for women with a positive tolerance-hyperbaric test
Number of subjects: 240
Study 10523401 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or placebo
Number of subjects: 240
Study 10523401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (any time)
Number of subjects: 240
Study 7573253 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure (maternal prenatal exposure)
Number of subjects: 542
Study 7573253 — intervention group
Group type: COMPARATOR
Intervention: Unexposed to diethylstilbestrol (control group)
Number of subjects: 542
Study 2147831 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 micrograms/kg/min for 30 minutes then 10 micrograms/kg/min
Number of subjects: 20
Study 2147831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 10 micrograms/kg/min
Number of subjects: 20
Study 388762 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) - 14 daily doses in addition to standard immunosuppressive therapy (azathioprine and prednisone)
Number of subjects: 358
Study 388762 — intervention group
Group type: COMPARATOR
Intervention: Control group - no ATG
Number of subjects: 358
Study 388762 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) - 14 daily doses
Number of subjects: 358
Study 31172407 — intervention group
Group type: EXPERIMENTAL
Intervention: GC+w‐iniparib (iniparib 11.2 mg/kg on days 1 and 8 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Number of subjects: 163
Study 31172407 — intervention group
Group type: COMPARATOR
Intervention: GC+tw‐iniparib (iniparib 5.6 mg/kg on days 1, 4, 8, and 11 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Number of subjects: 163
Study 29190741 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS)
Number of subjects: 40
Study 26835867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program on recommended sleeping position
Number of subjects: 20
Study 26835867 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 20
Study 23938061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25 to 4 mg)
Number of subjects: 404
Study 23938061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 21761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maixuekang capsule
Number of subjects: 214
Study 21761740 — intervention group
Group type: COMPARATOR
Intervention: Low molecular heparin calcium (Subilin)
Number of subjects: 214
Study 21761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maixuekang capsule and low molecular heparin calcium (Subilin)
Number of subjects: 214
Study 19969158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 3 times a week for 12 weeks)
Number of subjects: 50
Study 19969158 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (relaxation/stretching) program
Number of subjects: 50
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 9
Study 16413249 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 9
Study 15288906 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving school
Number of subjects: 47
Study 15288906 — intervention group
Group type: COMPARATOR
Intervention: Traditional school
Number of subjects: 47
Study 15288906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 11740289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-station proprioceptive exercise program
Number of subjects: 30
Study 11740289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 9415513 — intervention group
Group type: EXPERIMENTAL
Intervention: Monozygotic twins (MZ)
Number of subjects: 609
Study 9415513 — intervention group
Group type: COMPARATOR
Intervention: Dizygotic twins (DZ)
Number of subjects: 609
Study 9415513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for confounding variables
Number of subjects: 609
Study 9415513 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of dolorimeter measurements
Number of subjects: 609
Study 9415513 — intervention group
Group type: EXPERIMENTAL
Intervention: Heritability of PPT
Number of subjects: 609
Study 8237624 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 80
Study 8237624 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 80
Study 2434815 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 low-molecular-weight heparinoid
Number of subjects: 75
Study 2434815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30985238 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Pro-Social (GPS) program
Number of subjects: 254
Study 30985238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 28475565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand protocols facilitated by height-adjustable workstations
Number of subjects: 26
Study 28475565 — intervention group
Group type: COMPARATOR
Intervention: Usual sitting (control)
Number of subjects: 26
Study 25433821 — intervention group
Group type: EXPERIMENTAL
Intervention: MyTeachingPartner (MTP) coaching intervention
Number of subjects: 0
Study 23531633 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia (HTEA)
Number of subjects: 64
Study 23531633 — intervention group
Group type: COMPARATOR
Intervention: Standard balanced general anesthesia (Control)
Number of subjects: 64
Study 21565525 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms assessment using the Hopkins Symptom Checklist‐Depression Scale
Number of subjects: 1044
Study 21565525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age, intimate partner violence, illicit drug and alcohol use during pregnancy, reproductive history
Number of subjects: 1044
Study 21565525 — intervention group
Group type: EXPERIMENTAL
Intervention: Being very happy about the pregnancy, having emotional support from others, reporting more positive expectancies about the ability to regulate negative moods
Number of subjects: 1044
Study 19092462 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 57
Study 19092462 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine 2% jelly
Number of subjects: 57
Study 16284061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of ethinyl estradiol (EE) 20 microg in the morning and placebo at night
Number of subjects: 179
Study 16284061 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 179
Study 16284061 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of twice daily placebo
Number of subjects: 179
Study 16284061 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 179
Study 15124154 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the Diagnostic Interview for Genetic Studies (DIGS-K)
Number of subjects: 53
Study 11771434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyco A cream (12% glycolic acid)
Number of subjects: 40
Study 11771434 — intervention group
Group type: COMPARATOR
Intervention: Kefrane cream (0.05% retinoic acid)
Number of subjects: 40